See more : ServisFirst Bancshares, Inc. (SFBS) Income Statement Analysis – Financial Results
Complete financial analysis of Kyverna Therapeutics, Inc. (KYTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kyverna Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Blue Ridge Bankshares, Inc. (BRBS) Income Statement Analysis – Financial Results
- Daan Gene Co., Ltd. (002030.SZ) Income Statement Analysis – Financial Results
- CO2 Solutions Inc. (COSLF) Income Statement Analysis – Financial Results
- Kuzbasskaya Toplivnaya Kompaniya PAO (KBTK.ME) Income Statement Analysis – Financial Results
- Air T, Inc. (AIRTP) Income Statement Analysis – Financial Results
Kyverna Therapeutics, Inc. (KYTX)
About Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Metric | 2023 | 2022 | 2021 |
---|---|---|---|
Revenue | 0.00 | 7.03M | 5.66M |
Cost of Revenue | 1.71M | 1.05M | 586.00K |
Gross Profit | -1.71M | 5.97M | 5.07M |
Gross Profit Ratio | 0.00% | 85.04% | 89.64% |
Research & Development | 49.92M | 28.40M | 25.85M |
General & Administrative | 12.48M | 8.01M | 6.15M |
Selling & Marketing | 0.00 | 0.00 | 0.00 |
SG&A | 12.48M | 8.01M | 6.15M |
Other Expenses | -55.00K | -9.00K | -2.00K |
Operating Expenses | 62.41M | 36.41M | 32.00M |
Cost & Expenses | 62.41M | 36.41M | 32.00M |
Interest Income | 2.28M | 565.00K | 1.00K |
Interest Expense | 187.00K | 65.00K | 3.00K |
Depreciation & Amortization | 1.71M | 1.05M | 586.00K |
EBITDA | -58.47M | -27.78M | -25.76M |
EBITDA Ratio | 0.00% | -395.40% | -455.46% |
Operating Income | -62.41M | -29.38M | -26.35M |
Operating Income Ratio | 0.00% | -418.28% | -465.81% |
Total Other Income/Expenses | 2.04M | 491.00K | -4.00K |
Income Before Tax | -60.37M | -28.89M | -26.35M |
Income Before Tax Ratio | 0.00% | -411.29% | -465.88% |
Income Tax Expense | 0.00 | 56.00K | 1.00K |
Net Income | -60.37M | -28.89M | -26.35M |
Net Income Ratio | 0.00% | -411.29% | -465.88% |
EPS | 0.00 | -1.12 | -1.02 |
EPS Diluted | 0.00 | -1.12 | -1.02 |
Weighted Avg Shares Out | 673.62M | 25.80M | 25.80M |
Weighted Avg Shares Out (Dil) | 673.62M | 25.80M | 25.80M |
KYTX Investors Are Encouraged By The Schall Law Firm To Participate In The Kyverna Therapeutics Inc Securities Fraud Investigation
KYTX Shareholders Are Encouraged By The Schall Law Firm To Participate In The Securities Fraud Investigation Into Kyverna Therapeutics Inc
KYTX Investors Are Urged By The Schall Law Firm To Be Part Of The Securities Fraud Inquiry Into Kyverna Therapeutics Inc
KYTX Stakeholders Are Encouraged By The Schall Law Firm To Participate In The Securities Deception Investigation Into Kyverna Therapeutics Inc
KYTX Shareholders Are Encouraged By The Schall Law Firm To Participate In The Securities Fraud Investigation Into Kyverna Therapeutics Inc
KYTX Shareholders Are Invited By The Schall Law Firm To Join The Securities Fraud Probe Into Kyverna Therapeutics Inc
The Schall Law Firm Is Conducting A Securities Fraud Investigation Into Kyverna Therapeutics Inc And Invites KYTX Shareholders To Participate
Kyverna Therapeutics Inc And KYTX Stock Proprietors Are Welcomed To Engage In A Securities Fraud Examination Performed By The Schall Law Firm
Kyverna Therapeutics Inc And KYTX Stock Possessors Are Requested To Be Part Of A Securities Fraud Inquiry Carried Out By The Schall Law Firm
Kyverna Therapeutics Inc And KYTX Stock Holders Are Invited To Join A Securities Fraud Probe Conducted By The Schall Law Firm
Source: https://incomestatements.info
Category: Stock Reports